Actively Recruiting
A Phase 2A Trial of DT402 for Autism Spectrum Disorder
Led by Definium Therapeutics US, Inc. · Updated on 2026-04-06
20
Participants Needed
1
Research Sites
86 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder
CONDITIONS
Official Title
A Phase 2A Trial of DT402 for Autism Spectrum Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Autism Spectrum Disorder confirmed by standard semi-structured interview (e.g., Autism Diagnostic Observation Schedule-Second Edition)
- Male or Female aged 18 to 65 years
- Clinically significant deficits in socialization and communication as indicated by Social Responsiveness Scales (SRS-2) score of 66 or higher
You will not qualify if you...
- Uncorrected abnormalities in eye movement, alignment, or acuity, or atypical eye features that could interfere with eye tracking
- First-degree relative with or lifetime history of psychotic disorder or bipolar disorder
- Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
- Any clinically significant unstable illness
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Spectrum Neuroscience and Treatment Institute
New York, New York, United States, 10021
Actively Recruiting
Research Team
D
Definium Therapeutics Clinical Trials Information Requests
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here